Mesalazina Sandoz (Mesalazine)

Mesalazine works by locally inhibiting cyclooxygenase and lipoxygenase enzymes in the colon, which lowers the production of prostaglandins and leukotrienes. This reduction in inflammatory mediators decreases mucosal inflammation and promotes healing of the intestinal lining.

The prescribed dose of Mesalazina Sandoz is determined by the treating physician based on the severity of disease, patient weight, renal function, and response to therapy. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without self‑adjustment.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate individual circumstances before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mesalazina Sandoz delivers mesalazine directly to the colon, offering a targeted anti‑inflammatory effect similar to other 5‑ASA agents such as sulfasalazine. Compared with sulfasalazine, it lacks the sulfapyridine moiety, which can reduce systemic side effects and improve tolerability for some patients.

Store Mesalazina Sandoz at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Mesalazina Sandoz is administered rectally, typically as an enema or suppository. The patient should follow the prescribing information, which includes instructions on positioning, dosage volume, and frequency of administration to ensure optimal drug delivery to the colon.

Serious risks include severe allergic reactions such as anaphylaxis, blood disorders like neutropenia, liver injury, interstitial nephritis, and acute pancreatitis. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Mesalazina Sandoz should be avoided in individuals with known hypersensitivity to mesalazine or any component of the formulation, as well as in patients with severe renal or hepatic impairment where the risk may outweigh benefit. Contraindications should be confirmed by the prescribing clinician.